Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Chemical Industry News Reward Minerals strikes gold with Beyondie Potash Plant—what this means for the industry In a significant move that could reshape Australia’s sulphate of potash industry, Reward Minerals Limited has announced its… byPallavi MadhirajuSeptember 30, 2024